Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SGHT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSight Sciences wins $34M patent verdict against Alcon, but collection hinges on appeals
Filed March 30, 2026 · Period ending March 27, 2026 · ~1 min read
Key Changes
-
high
Court upheld jury verdict that Alcon willfully infringed three Sight Sciences patents, awarding $34M in damages plus 10% ongoing royalty on Hydrus revenue through November 2028.
Item 8.01 view on EDGAR → -
high
No cash will be collected until Alcon exhausts appeals or appeal deadline passes, meaning actual payment could be delayed significantly.
Item 8.01 view on EDGAR → -
high
Alcon is challenging patent validity through USPTO reexamination. If patents are invalidated before litigation becomes final, Sight Sciences may be unable to collect the judgment.
Item 8.01 view on EDGAR → -
medium
USPTO previously denied Alcon's 2023 attempts to invalidate two of the three patents, finding no material examiner error in the original patent review.
Item 8.01 view on EDGAR →
Summary
Sight Sciences secured a major legal victory when a Delaware federal court preserved a jury's finding that Alcon willfully infringed three patents related to the Hydrus Microstent. The court awarded $34 million in damages plus supplemental amounts and a 10% ongoing royalty through November 2028. This represents validation of Sight Sciences' intellectual property in litigation that began in September 2021.
However, retail investors should understand this is not yet money in the bank. Sight Sciences cannot collect a dollar until Alcon completes its appeals or the appeal window closes. More concerning, Alcon has opened a parallel front at the USPTO seeking to invalidate the patents through reexamination.
If the USPTO invalidates the patents and that decision becomes final before the court judgment does, Sight Sciences could lose the entire award. Watch for two key developments: whether Alcon files an appeal of the court judgment, and the outcome of the USPTO reexamination proceedings. The USPTO previously rejected similar Alcon challenges in 2023, which is encouraging but not dispositive. Until both processes resolve in Sight Sciences' favor, the $34 million remains contingent.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Final Judgment is subject to appeal by Alcon. No monetary damages will be recovered by the Company until Alcon exhausts its rights to appeal or the time for filing an appeal has passed.
While the court order is favorable, Sight Sciences will not collect any monetary damages until Alcon completes its appeal process or the appeal deadline passes. The final judgment has not yet been entered and is expected in coming months after supplemental damages and pre-judgment interest are calculated. This means actual cash recovery could be delayed significantly.
Added in current filing · verify on EDGAR →
In June 2025, Alcon filed petitions for ex parte reexamination (“EPR”) with the U.S. Patent and Trademark Office (“USPTO”) challenging the validity of the claims in the Patents that the Company had asserted at trial, based on prior art patents and publications. The USPTO is reexamining the validity of these claims, and any final office actions by the USPTO, if adverse to the Company, are subject to multiple layers of appeal by the Company, initially within the USPTO, and then to the Federal Circuit Court of Appeals.
Alcon has challenged the validity of the asserted patent claims through ex parte reexamination proceedings at the USPTO. The USPTO is currently reviewing whether the patents are valid based on prior art. If the USPTO ultimately invalidates the patents and that decision is upheld on appeal, it could undermine Sight Sciences' ability to collect on the judgment.
Added in current filing · verify on EDGAR →
If an adverse, final and non-appealable judgment from one or more of the EPRs is entered by the Federal Circuit Court of Appeals before a final and non-appealable judgment from the Litigation is entered by that same appeals court in the Company’s favor, it could negatively affect the Company’s ability to collect on the Final Judgment.
There is a timing risk where if the USPTO reexamination process results in patent invalidation that becomes final before the litigation judgment becomes final, Sight Sciences may be unable to collect the awarded damages. This creates uncertainty around whether the company will ultimately receive the $34 million award and ongoing royalties.
Added in current filing · verify on EDGAR →
Previously, Alcon filed petitions for inter partes review challenging the validity of two of the three patents that Sight Sciences presented at trial. Those petitions were denied by the USPTO in March 2023, which concluded in each case that instituting a review of the validity of the petitioned patents was unwarranted. The USPTO found that the same or substantially the same prior art and arguments previously had been presented to it during examination of the petitioned patents, and Alcon had not demonstrated that the USPTO patent examiner materially erred when considering the prior art.
In March 2023, the USPTO denied Alcon's earlier attempts to invalidate two of the three patents through inter partes review, finding that Alcon's prior art arguments had already been considered during patent examination and showed no material error. This provides some historical support for the patents' validity, though the current ex parte reexamination proceedings remain pending.
Event · Item 9.01 — Financial Statements and Exhibits
Sight Sciences filed an 8-K attaching a press release dated March 30, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1 Press Release dated March 30, 2026
The 8-K lists a press release dated March 30, 2026 as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature of the announcement cannot be determined from this 8-K alone.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify